Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma

BACKGROUND & OBJECTIVES: Inhibitors of immune checkpoint regulators, programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1), improve outcome in advanced non-small-cell lung carcinoma (NSCLC). Tumours expressing PD-L1 protein are more likely to benefit from this targeted therapy. Multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Nambirajan, Aruna, Husain, Nuzhat, Shukla, Saumya, Kumar, Sunil, Jain, Deepali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902360/
https://www.ncbi.nlm.nih.gov/pubmed/31823919
http://dx.doi.org/10.4103/ijmr.IJMR_367_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902360/
https://www.ncbi.nlm.nih.gov/pubmed/31823919
http://dx.doi.org/10.4103/ijmr.IJMR_367_18

Ejemplares similares